Log in to save to my catalogue

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7745180

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In a trial involving 1033 patients hospitalized with Covid-19, the addition of baricitinib to remdesivir was associated with shorter recovery time, particularly among patients receiving high-flow oxygen, and with a 30% higher odds of improvement at day 15 than remdesivir alone. Adverse events were less frequent with the combination therapy.

Alternative Titles

Full title

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7745180

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7745180

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2031994

How to access this item